Agent Capital — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
HealthtechBoston, US
John Flavin(Director)Lucio Iannone(Director)
BoardDavid Steinberg(Executive Officer, Director)Christoph Westphal(Director)Jak Knowles(Director)
Board seatGeeta Vemuri· per SEC Form D · $22M raise · filed Jul 2019
Co-investorsLongwood FundRA Capital
BiotechWarrington, US
Mary B. Templeton(Executive Officer)Craig E. Fraser(Executive Officer, Director)Lawrence A. Weinstein(Executive Officer)Kathryn Cole(Executive Officer)John Tattory(Executive Officer)George Cox(Executive Officer)
Board seatBruce Peacock· per SEC Form D · $26.4M raise · filed Dec 2019
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Susan B Dillon(Executive Officer, Director)Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)Mark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)
Board seatBruce Peacock· per SEC Form D · $5M raise · filed Jan 2020
Co-investorsAvego BioScience CapitalHealthCap
Ocular is a clinical-stage biopharmaceutical company developing AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel, aimed at reducing the treatment burden of retinal diseases.
BiotechHealthtechMedical DevicesBedford, US
Amarpreet Sawhney(Director)Michael Goldstein(Executive Officer)Daniel Bollag(Executive Officer)Antony Mattessich(Executive Officer, Director)Donald Notman(Executive Officer)W. James O'Shea(Director)
Board seatBruce Peacock· per SEC Form D · $37.5M raise · filed Mar 2019
Co-investorsAscension VenturesSofinnova VenturesSV Health InvestorsTop Corner Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.